Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Apr 5;9(1):5688.
doi: 10.1038/s41598-019-42059-3.

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease

Sang Bong Ahn  1 , Dae Won Jun  2 , Bo-Kyeong Kang  3 , Jong Hyun Lim  4 , Sanghyun Lim  4 , Myung-Jun Chung  4
Affiliations
Randomized Controlled Trial

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease

Sang Bong Ahn et al. Sci Rep. .

Abstract

The intestinal microbiota is closely associated with the development of obesity and nonalcoholic fatty liver disease (NAFLD). This study investigated the effects of probiotic treatment on visceral fat area (VFA) and intrahepatic fat (IHF) fraction in NAFLD. Sixty-eight obese NAFLD patients (>5% proton density fat fraction [PDFF] on magnetic resonance imaging [MRI]) were randomized to probiotic and placebo groups for 12 weeks. The probiotic mixture included 6 bacterial species. VFA and IHF were measured using the MRI-PDFF technique. Body weight and total body fat were reduced in the probiotic group but not in the placebo group. The mean IHF fraction was reduced after 12 weeks of treatment in the probiotic group compared to that at baseline (from 16.3 ± 15.0% to 14.1 ± 7.7%, p = 0.032) but was not reduced in the placebo group. The decrease in IHF (mean difference: -2.61%, p = 0.012) was also greater in the probiotic group than in the placebo group. Reduction of triglyceride was greater in the probiotic treatment group than in the placebo group (mean difference: -34.0 mg/dl, p = 0.0033). However, the changes in IHF percentage and triglyceride levels were not different between placebo and control groups after adjusting for changes in body weight. Treatment with probiotics for 12 weeks resulted in significant reduction in IHF and body weight in obese NAFLD patients.

PubMed Disclaimer

Conflict of interest statement

Jong Hyun Lim, Sanghyun Lim and Myung-Jun Chung are full-time employee of CELLBIOTECH. Sang Bong Ahn, Dae Won Jun and Bo-Kyeong Kang have nothing to disclose.

Figures

Figure 1
Figure 1
Consort flow chart.
Figure 2
Figure 2
Changes in weight and body fat according to treatment.
Figure 3
Figure 3
Changes in hepatic fat content in probiotic and placebo groups. (A) Individual patient data for hepatic fat content as assessed using MRI-PDFF at baseline and 12 weeks. The probiotic group had a significant reduction in hepatic fat after 12 weeks of treatment. (B) In the probiotic group, 40.0% showed a significant reduction in IHF, with no difference in 46.7% and worsening in 13.3%. In the control group, 17.1% showed a significant reduction in IHF, with no difference in 51.4% and worsening in 31.4%. More significant reduction in IHF was shown in the probiotic group than in the control group (40% vs. 17.1%, p = 0.038).
See this image and copyright information in PMC

References

    1. Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–609. doi: 10.1002/hep.26093. - DOI - PubMed
    1. Li Z, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350. doi: 10.1053/jhep.2003.50048. - DOI - PubMed
    1. Mencarelli A, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One. 2012;7:e45425. doi: 10.1371/journal.pone.0045425. - DOI - PMC - PubMed
    1. Mencarelli A, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e22978. doi: 10.1371/journal.pone.0022978. - DOI - PMC - PubMed
    1. Aller R, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090–1095. - PubMed

Publication types